Sign In
Buy CLDX
$33.41
+0.98 (+3.02%)
At Close: Jun 22, 2026
Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market
03:14pm, Monday, 04'th Nov 2024
Celldex's primary revenue driver is Barzolvolimab, now in Phase 3 for CSU, targeting unmet needs in inflammatory diseases. Barzolvolimab has shown strong Phase 2 efficacy for CSU, though safety concer
HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most
HAMPTON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that 12 week results from the Company's Phase 2 clinical trial of barzolvolimab in two of the
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study
11:30am, Thursday, 26'th Sep 2024
Celldex stock falls due to safety concerns related to the treatment of urticaria patients with barzolvolimab in a phase II study, despite robust efficacy data.
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
10:45am, Wednesday, 25'th Sep 2024
- 71% of patients (150 mg Q4W) achieved complete response at Week 52 - - Rapid, profound and durable improvement in UAS7 as early as Week 1 with a deepening of response over 52 weeks - - Robust improv
HAMPTON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that an abstract describing 52 week results from the Company's Phase 2 clinical trial of barz
Celldex Therapeutics to Present at Upcoming Investor Conferences
04:01pm, Thursday, 12'th Sep 2024
HAMPTON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
06:25pm, Thursday, 08'th Aug 2024
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.65 per share a year ago.
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
04:01pm, Thursday, 08'th Aug 2024
HAMPTON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2024 and provided a corporate update.
Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
04:01pm, Monday, 29'th Jul 2024
HAMPTON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive topline results from the Company's Phase 2 clinical trial of barzolvolimab in two of
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
08:01am, Tuesday, 16'th Jul 2024
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients -
Celldex Therapeutics to Present at Jefferies Healthcare Conference
04:01pm, Tuesday, 04'th Jun 2024
HAMPTON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on
- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups - - Sustained activity with rapid onset within 2 weeks - - Data
Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet
11:00am, Monday, 27'th May 2024
The mean of analysts' price targets for Celldex (CLDX) points to an 87.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Purchased by Swiss National Bank
04:43am, Monday, 20'th May 2024
Swiss National Bank boosted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 9.9% in the fourth quarter, according to its most recent disclosure with the SEC. The
